A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.
Publication
, Journal Article
Morrison, VA; Johnson, JL; Jung, S; Leonard, JP; Cheson, BD
Published in: Journal of Clinical Oncology
May 20, 2010
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
8106 / 8106
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Morrison, V. A., Johnson, J. L., Jung, S., Leonard, J. P., & Cheson, B. D. (2010). A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. Journal of Clinical Oncology, 28(15_suppl), 8106–8106. https://doi.org/10.1200/jco.2010.28.15_suppl.8106
Morrison, V. A., J. L. Johnson, S. Jung, J. P. Leonard, and B. D. Cheson. “A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 8106–8106. https://doi.org/10.1200/jco.2010.28.15_suppl.8106.
Morrison VA, Johnson JL, Jung S, Leonard JP, Cheson BD. A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. Journal of Clinical Oncology. 2010 May 20;28(15_suppl):8106–8106.
Morrison, V. A., et al. “A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 8106–8106. Crossref, doi:10.1200/jco.2010.28.15_suppl.8106.
Morrison VA, Johnson JL, Jung S, Leonard JP, Cheson BD. A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):8106–8106.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
8106 / 8106
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences